3%(99%CI6–36;p=0·0005)inparticipantswhohadLDLcholesterolof2·0–2·5mmol/Lreducedfurtherandof29%(99%CI2–48;p=0·007)inthosewhohadLDLcholesterollowerthan2·0mmol/L(mean1·71mmol/L)reducedfurther.TheLancet.PublishedOnlineNovember9,2010DOI:10.1016/S0140-6736(10)61350-5中国第二次血脂治疗现状调研结果?中国大部分高危/极高危患者未能达标(采用2004年ATPⅢ的危险分层)N=1632N=756N=637N=112N=127LDL<70mg/dlLDL<100mg/dlLDL<130mg/dlLDL<160mg/dl49%62%47%22%9%所有患者均采用他汀单药治疗60%60%61%64%36%未达标%未达标者距离指南目标值>18mg/dL的%LDL-C达标率低的原因重视程度不足,未积极合理的应用他汀患者不能耐受他汀治疗患者不能耐受较大剂量他汀治疗应用较大剂量他汀后LDL-C仍不能达标10204080LDL-C降幅(%)mg他汀-10-20-30+10mg-6%+20mg-6%+40mg-6%-40-50他汀类的“6规则”LeitersdorfE.Eur.HeartJ.2001(Suppl)3:E17-E23阿托伐他汀洛伐他汀20mg40mg80mg20mg40mg80mg辛伐他汀40mg80mg40mg80mg1.7x2.3xLDL-C降幅%10mg20mg40mg80mg-60-50-40-30-20-10010mg20mg40mg80mg0.00.51.01.52.02.5转氨酶升高(患者%)4x他汀剂量加倍的风险/获益比
全文预览
